High-Dose Vitamin D 4,000 IU Cuts Autoimmune Relapse and MRI Lesion Burden in Women: D-LayMS, VITAL, and the Emerging Consensus

A new clinical consensus is forming around vitamin D supplementation. A 2025 Frontiers in Immunology review consolidated high-dose vitamin D data across multiple sclerosis (MS), rheumatoid arthritis, Crohn’s disease, lupus, and vitiligo. The verdict: at 4,000~5,000 IU/day, relapse rates and imaging lesion burden drop meaningfully. Female-majority trials (46~94%) dominated, and the strongest responses appeared in patients with baseline serum 25(OH)D below 30 ng/mL.

The most decisive data came from D-LayMS. The trial gave 316 early MS patients 100,000 IU cholecalciferol biweekly (averaging ~7,142 IU/day) for 24 months, producing significant reductions in relapse rate and MRI lesion accumulation versus placebo. The Hupperts RCT added high-dose daily vitamin D3 to subcutaneous interferon beta-1a in relapsing-remitting MS patients with the same direction of effect. Neither trial showed safety signals (hypercalcemia, kidney stones).

The dose threshold is around 4,000 IU. The Cassard trial at 5,000 IU/day did not show meaningful difference, but many enrolled patients had adequate baseline 25(OH)D. The Aranow lupus trial at 2,000~4,000 IU did not reduce interferon signature. By contrast, the Bendix Crohn’s trial at 20,000 IU/day for 7 weeks cut infliximab dose escalation requirements by 25%, and the Finamor psoriasis/vitiligo trial at 35,000 IU/day for 6 months was effective and safe. The pattern is clear: the deeper the deficiency, the higher the autoimmune activity, the larger the dose, the more pronounced the effect.

Vitamin D’s autoimmune modulation runs through several layers. In T cells, suppression of Th17 (autoimmunity-promoting) and activation of Tregs (regulatory). In B cells, dampened autoantibody production. In dendritic cells, reduced immunogenicity, increased tolerance induction. In macrophages, attenuated NF-κB signaling. Vitamin D receptor (VDR) is present on essentially all immune cells for direct action. At the same time, in skin keratinocytes vitamin D drives cathelicidin (LL-37) production, boosting antimicrobial peptide activity. Autoimmunity and infection defense balance on the same molecule.

Women carry the burden disproportionately. About 80% of autoimmune disease occurs in women — rheumatoid arthritis, lupus, multiple sclerosis, Hashimoto’s thyroiditis, celiac, Sjögren’s are all female-dominant. The crossroads of estrogen signaling and immune cell activity is the underlying explanation. And vitamin D deficiency rates in Korean women are striking: national health survey data show over 90% of women aged 20~40 have 25(OH)D below 30 ng/mL, and 60~70% are below 20 ng/mL. The cumulative result of UV avoidance, daily sunscreen use, and indoor lifestyle.

A daily 4,000 IU dose is generally considered safe within tolerable upper limits. The US IOM upper limit is 4,000 IU/day; the Endocrine Society allows up to 10,000 IU/day. In deficient patients, a clinical protocol of 50,000 IU weekly short-term followed by 4,000 IU maintenance is common. Sarcoidosis, tuberculosis, certain lymphomas, severe kidney disease, and calcium-metabolism disorders require physician oversight. Cholecalciferol (D3) raises serum 25(OH)D more effectively than ergocalciferol (D2).

The takeaway: anyone with an autoimmune diagnosis or family history should start with a baseline 25(OH)D test; if you’re in the deficiency range (below 20 ng/mL), 4,000 IU/day is clinically justified; and the threshold “below 30 ng/mL” is increasingly treated as deficiency in autoimmune patients. The vast majority of Korean women qualify for supplementation.